A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism

NCT01441804 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis C

Interventions

DRUG: Peginterferon alfa2a
DRUG: Ribavirin
DRUG: Peginterferon alfa2a
DRUG: Ribavirin

Sponsor

Third Affiliated Hospital, Sun Yat-Sen University